Heghine Khachatryan: New Evidence in Secondary Stroke Prevention: Cilostazol + Aspirin vs Ticagrelor + Aspirin
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by International Journal of Stroke on LinkedIn:
“New evidence in secondary stroke prevention
A recent study published in the International Journal of Stroke reports that cilostazol plus aspirin significantly reduces recurrent stroke, myocardial infarction, and vascular death, with comparable efficacy to ticagrelor plus aspirin in the acute-phase treatment of large-vessel disease.
Why this matters
• Provides an alternative dual antiplatelet strategy with proven effectiveness
• Particularly relevant for patients with high bleeding risk, intolerance, or contraindications to potent P2Y12 inhibitors
• Highlights the growing role of cilostazol-based regimens beyond East Asian populations
-This study adds valuable data to ongoing discussions on individualized antiplatelet therapy after ischemic stroke and reinforces the need to balance efficacy with safety.
Full article: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel disease”
Quoting International Journal of Stroke‘s post:
“Study finds cilostazol plus aspirin reduced recurrent stroke, MI, and vascular death with a comparable rate to ticagrelor plus aspirin
However, cilostazol plus aspirin showed significantly lower rates of hemorrhagic complications and better tolerability
Read more here.”
Title: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial
Authors: Mohamed Ismaiel, Sherihan Rezk ahmed et al.
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention
-
Oct 17, 2026, 02:00How Antiphospholipid Syndrome Can Affect the Adrenal Glands – APS Foundation of America
-
Oct 17, 2026, 01:59Liza-Marie Johnson: How Far Should Clinicians Go to Influence Parents’ Decisions?
-
Oct 17, 2026, 01:54Jim Hoffman: The Importance of Self-Advocacy and Understanding Autoimmune Mechanisms